ReviewAdvanced drug delivery reviews2010
Application of nanotechnologies for improved immune response against infectious diseases in the developing world.
Review in Advanced drug delivery reviews, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Overcoming resistance mechanisms in cancer immunotherapy-novel approaches and combinations.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Nanotechnology in oncology: advances in biosynthesis, drug delivery, and theranostics.Discover oncology · 2025Review
- Revolutionizing Nanovaccines: A New Era of Immunization.Vaccines · 2025Review
- EngineeringVaccines · 2024Review
- Nanomedicines as a cutting-edge solution to combat antimicrobial resistance.RSC advances · 2024Review
- Challenges and Prospective of Enhancing Hydatid Cyst Chemotherapy by Nanotechnology and the Future of Nanobiosensors for Diagnosis.Tropical medicine and infectious disease · 2023Review
- Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation.ACS omega · 2023Review
- Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines.International journal of biological macromolecules · 2023Review
- Insights into innovative therapeutics for drug-resistant tuberculosis: Host-directed therapy and autophagy inducing modified nanoparticles.International journal of pharmaceutics · 2022Article
- Anti-COVID-19 Nanomaterials: Directions to Improve Prevention, Diagnosis, and Treatment.Nanomaterials (Basel, Switzerland) · 2022Review
- Application of Nanomaterials as an Advanced Strategy for the Diagnosis, Prevention, and Treatment of Viral Diseases.Pharmaceutics · 2021Review
- Metal Nanoparticles: a Promising Treatment for Viral and Arboviral Infections.Biological trace element research · 2021Review
- Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19.ACS biomaterials science & engineering · 2021Review
- Advancements in protein nanoparticle vaccine platforms to combat infectious disease.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2021Review
- Effect of physicochemical properties onActa pharmaceutica Sinica. B · 2021Review
- DNA Nanostructures in the Fight Against Infectious Diseases.Advanced nanobiomed research · 2021Article
- Nanomedicine for the SARS-CoV-2: State-of-the-Art and Future Prospects.International journal of nanomedicine · 2021Review
- Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases.Frontiers in immunology · 2021Review
- Tri-mannose grafting of chitosan nanocarriers remodels the macrophage response to bacterial infection.Journal of nanobiotechnology · 2019Article
- DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy.Frontiers in pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
There is an urgent need for new strategies to combat infectious diseases in developing countries. Many pathogens have evolved to elude immunity and this has limited the utility of current therapies. Additionally, the emergence of co-infections and drug resistant pathogens has increased the need for advanced therapeutic and diagnostic strategies. These challenges can be addressed with therapies that boost the quality and magnitude of an immune response in a predictable, designable fashion that can be applied for wide-spread use. Here, we discuss how biomaterials and specifically nanoscale delivery vehicles can be used to modify and improve the immune system response against infectious diseases. Immunotherapy of infectious disease is the enhancement or modulation of the immune system response to more effectively prevent or clear pathogen infection. Nanoscale vehicles are particularly adept at facilitating immunotherapeutic approaches because they can be engineered to have different physical properties, encapsulated agents, and surface ligands. Additionally, nanoscaled point-of-care diagnostics offer new alternatives for portable and sensitive health monitoring that can guide the use of nanoscale immunotherapies. By exploiting the unique tunability of nanoscale biomaterials to activate, shape, and detect immune system effector function, it may be possible in the near future to generate practical strategies for the prevention and treatment of infectious diseases in the developing world.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.